{"id":"https://openalex.org/W2116799993","doi":"https://doi.org/10.1186/2050-6511-13-18","title":"Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study","display_name":"Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study","publication_year":2012,"publication_date":"2012-12-01","ids":{"openalex":"https://openalex.org/W2116799993","doi":"https://doi.org/10.1186/2050-6511-13-18","mag":"2116799993","pmid":"https://pubmed.ncbi.nlm.nih.gov/23254273","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3554536"},"language":"en","primary_location":{"id":"doi:10.1186/2050-6511-13-18","doi":"https://doi.org/10.1186/2050-6511-13-18","is_oa":true,"landing_page_url":"https://doi.org/10.1186/2050-6511-13-18","pdf_url":"https://bmcpharmacoltoxicol.biomedcentral.com/track/pdf/10.1186/2050-6511-13-18","source":{"id":"https://openalex.org/S29101735","display_name":"BMC Pharmacology and Toxicology","issn_l":"2050-6511","issn":["2050-6511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Pharmacology and Toxicology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://bmcpharmacoltoxicol.biomedcentral.com/track/pdf/10.1186/2050-6511-13-18","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Thomas Babcock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Thomas Babcock","raw_affiliation_strings":["Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA. tbabcock@shire.com","Shire Development, LLC, Wayne, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA. tbabcock@shire.com","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Shire Development, LLC, Wayne, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048922429","display_name":"Bryan Dirks","orcid":"https://orcid.org/0000-0001-6472-1606","observed_orcids":["https://orcid.org/0000-0001-6472-1606"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Dirks","raw_affiliation_strings":["Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA","Shire Development, LLC, Wayne, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Shire Development, LLC, Wayne, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064064053","display_name":"Ben A. Adeyi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ben Adeyi","raw_affiliation_strings":["Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA","Shire Development, LLC, Wayne, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Shire Development, LLC, Wayne, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026972521","display_name":"Brian Scheckner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Scheckner","raw_affiliation_strings":["Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA","Shire Development, LLC, Wayne, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Shire Development, LLC, Wayne, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210140176"],"apc_list":{"value":3090,"currency":"USD","value_usd":3090},"apc_paid":{"value":3090,"currency":"USD","value_usd":3090},"fwci":1.1916,"has_fulltext":true,"cited_by_count":14,"citation_normalized_percentile":{"value":0.75878884,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"13","issue":"1","first_page":"18","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lisdexamfetamine-dimesylate","display_name":"lisdexamfetamine dimesylate","score":0.9980000257492065},{"id":"https://openalex.org/keywords/adult-adhd","display_name":"adult ADHD","score":0.9150000214576721},{"id":"https://openalex.org/keywords/adhd-rs-iv","display_name":"ADHD-RS-IV","score":0.7829999923706055},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8700000047683716},{"id":"https://openalex.org/keywords/xerostomia","display_name":"xerostomia","score":0.5649999976158142},{"id":"https://openalex.org/keywords/headache","display_name":"headache","score":0.4869999885559082},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.35100001096725464},{"id":"https://openalex.org/keywords/electrocardiography","display_name":"electrocardiogram","score":0.5320000052452087},{"id":"https://openalex.org/keywords/stimulant-efficacy","display_name":"stimulant efficacy","score":0.492000013589859},{"id":"https://openalex.org/keywords/treatment-emergent-mania","display_name":"treatment-emergent mania","score":0.515999972820282}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.8470408916473389},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6220132112503052},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.6131528615951538},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5597958564758301},{"id":"https://openalex.org/C2777112843","wikidata":"https://www.wikidata.org/wiki/Q422112","display_name":"Methylphenidate","level":3,"score":0.5379095673561096},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.525807797908783},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5025253295898438},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.44837886095046997},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43144524097442627},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40810927748680115},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.38777002692222595},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3535288870334625},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069478","descriptor_name":"Lisdexamfetamine Dimesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D003627","descriptor_name":"Data Interpretation, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003913","descriptor_name":"Dextroamphetamine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003913","descriptor_name":"Dextroamphetamine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003913","descriptor_name":"Dextroamphetamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057915","descriptor_name":"Drug Substitution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1186/2050-6511-13-18","doi":"https://doi.org/10.1186/2050-6511-13-18","is_oa":true,"landing_page_url":"https://doi.org/10.1186/2050-6511-13-18","pdf_url":"https://bmcpharmacoltoxicol.biomedcentral.com/track/pdf/10.1186/2050-6511-13-18","source":{"id":"https://openalex.org/S29101735","display_name":"BMC Pharmacology and Toxicology","issn_l":"2050-6511","issn":["2050-6511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Pharmacology and Toxicology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2555269","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3554536","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:23254273","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23254273","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC pharmacology & toxicology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:3554536","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3554536/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Pharmacol Toxicol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1186/2050-6511-13-18","doi":"https://doi.org/10.1186/2050-6511-13-18","is_oa":true,"landing_page_url":"https://doi.org/10.1186/2050-6511-13-18","pdf_url":"https://bmcpharmacoltoxicol.biomedcentral.com/track/pdf/10.1186/2050-6511-13-18","source":{"id":"https://openalex.org/S29101735","display_name":"BMC Pharmacology and Toxicology","issn_l":"2050-6511","issn":["2050-6511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Pharmacology and Toxicology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2116799993.pdf","grobid_xml":"https://content.openalex.org/works/W2116799993.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W629283852","https://openalex.org/W1496028880","https://openalex.org/W1666727496","https://openalex.org/W1853960255","https://openalex.org/W1894252991","https://openalex.org/W1974896478","https://openalex.org/W1979206088","https://openalex.org/W2006463161","https://openalex.org/W2012950683","https://openalex.org/W2023323019","https://openalex.org/W2038799661","https://openalex.org/W2040977256","https://openalex.org/W2047554178","https://openalex.org/W2062714266","https://openalex.org/W2066420821","https://openalex.org/W2071199156","https://openalex.org/W2074521517","https://openalex.org/W2082580890","https://openalex.org/W2110145837","https://openalex.org/W2120173188","https://openalex.org/W2127512142","https://openalex.org/W2136110881","https://openalex.org/W2140787893","https://openalex.org/W2159184227","https://openalex.org/W2159881136","https://openalex.org/W2162170558","https://openalex.org/W2167062019","https://openalex.org/W3090293687","https://openalex.org/W3215125900"],"related_works":["https://openalex.org/W2120173188","https://openalex.org/W2129620184","https://openalex.org/W1979206088","https://openalex.org/W7096651025","https://openalex.org/W2080506224","https://openalex.org/W2182452737","https://openalex.org/W2343079611","https://openalex.org/W2127512142","https://openalex.org/W2131679908","https://openalex.org/W2012332062"],"abstract_inverted_index":{"BACKGROUND:":[0],"To":[1],"examine":[2],"the":[3,46,79,90,127,160,174,178,212,233,240,248,291,326,344,359],"efficacy":[4,64],"of":[5,65,286,341,363],"lisdexamfetamine":[6],"dimesylate":[7],"(LDX)":[8],"in":[9,39,69,126,152,177,239,247,259,290,319,343,365],"adults":[10,70,305],"with":[11,71,92,295,306,322,350],"attention-deficit/hyperactivity":[12],"disorder":[13],"(ADHD)":[14],"who":[15],"remained":[16,164],"symptomatic":[17,165],"(ADHD":[18],"Rating":[19],"Scale":[20],"IV":[21],"[ADHD-RS-IV]":[22],"total":[23,197,222],"score":[24],">18)":[25,167],"on":[26],"amphetamine":[27],"(AMPH)":[28],"therapy":[29,135],"(mixed":[30],"AMPH":[31,74,134,143,235,297,313],"salts":[32],"and/or":[33],"d-AMPH":[34],"formulations)":[35],"prior":[36,99,234,296],"to":[37,334,357],"enrollment":[38],"a":[40,56],"4-week":[41],"placebo-controlled":[42],"LDX":[43,66,156,184,249,262,323,342],"trial":[44],"vs":[45,78],"overall":[47,80,128,213,327,345],"study":[48,81,129,214,328,346],"population.":[49,329],"In":[50,232,300],"these":[51,287,301,336],"post":[52,302],"hoc":[53,303],"analyses":[54],"from":[55,194,204,219],"multicenter,":[57],"randomized,":[58],"double-blind,":[59],"forced-dose":[60],"titration":[61],"study,":[62],"clinical":[63],"(30-70":[67],"mg/d)":[68],"ADHD":[72,85,309,320],"receiving":[73,133,171],"treatment":[75,100,314,324],"at":[76,95,136,168,190],"screening":[77,137,169,195],"population":[82,347],"was":[83,145,348],"evaluated.":[84],"symptoms":[86,310,321],"were":[87,132,199,207,224,263],"assessed":[88],"using":[89],"ADHD-RS-IV":[91,196,221],"adult":[93],"prompts":[94],"screening,":[96],"baseline":[97,205,220,308],"(after":[98],"washout),":[101],"and":[102,115,147,154,183,201,203,209,228,243,281,361],"endpoint.":[103],"Safety":[104,360],"assessments":[105],"included":[106,125],"treatment-emergent":[107],"adverse":[108],"events":[109,288],"(TEAEs),":[110],"vital":[111],"signs,":[112],"laboratory":[113],"findings,":[114],"electrocardiogram.":[116],"RESULTS:":[117],"Of":[118,159],"414":[119],"participants":[120,151,176,246],"(62,":[121],"placebo;":[122,139],"352,":[123],"LDX)":[124],"population,":[130,215],"41":[131,161],"(2,":[138],"39,":[140],"LDX);":[141],"mean":[142,192,217],"dose":[144,315],"35.0":[146],"34.1":[148],"mg/d":[149],"for":[150,226,230,261],"placebo":[153,179,227,241,293],"all":[155],"groups,":[157,188],"respectively.":[158],"participants,":[162],"36":[163,175],"(ADHD-RS-IV":[166],"despite":[170,311],"AMPH.":[172],"For":[173,211],"(n":[180,185],"=":[181,186],"2)":[182],"34)":[187],"respectively,":[189],"endpoint,":[191],"change":[193,218],"scores":[198,206,223],"-5.5":[200],"-14.8":[202],"-13.5":[208],"-17.8.":[210],"endpoint":[216],"-7.8":[225],"-17.5":[229],"LDX.":[231],"subgroup,":[236],"2/2":[237],"(100.0%)":[238],"group":[242,252],"22/39":[244],"(56.4%)":[245],"(all":[250],"doses)":[251],"reported":[253],"any":[254],"TEAE.":[255],"Events":[256],"that":[257],"occurred":[258,289],"\u22655%":[260],"dry":[264],"mouth":[265],"(5/39;":[266,269],"12.8%),":[267,270],"headache":[268],"fatigue":[271],"(3/39;":[272,275],"7.7%),":[273,276],"insomnia":[274],"decreased":[277],"appetite":[278],"(2/39;":[279,283],"5.1%),":[280],"nausea":[282],"5.1%).":[284],"None":[285],"2":[292],"patients":[294],"use.":[298,353],"CONCLUSION:":[299],"analyses,":[304],"significant":[307],"adequate":[312],"showed":[316],"similar":[317],"improvements":[318],"as":[325],"Prospective":[330],"studies":[331],"are":[332],"needed":[333],"confirm":[335],"findings.":[337],"The":[338],"safety":[339],"profile":[340],"consistent":[349],"long-acting":[351],"psychostimulant":[352],"TRIAL":[354],"REGISTRY:":[355],"Study":[356],"Assess":[358],"Efficacy":[362],"NRP104":[364],"Adults":[366],"With":[367],"Attention-Deficit":[368],"Hyperactivity":[369],"Disorder":[370],"(ADHD).":[371],"Clinicaltrials.gov":[372],"Identifier:":[373],"NCT00334880.":[374]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}